Childhood Obesity: Case Discussion & Key Points
Model Case Presentation
Patient Demographics
Name: Master Rohan, Age: 11 years, Gender: Male, Informant: Mother (Reliable), Setting: Urban, middle-income family
Chief Complaints
- Excessive weight gain — 3 years
- Difficulty in physical activity and breathlessness on exertion — 1 year
- Snoring at night — 6 months
- Darkening of skin around neck — 1 year
History Summary
Rohan has been gaining weight progressively over the last 3 years. Diet history reveals high intake of fast food, sugary beverages, and snacks; low fruit and vegetable intake. Screen time is approximately 6–7 hours/day (TV + mobile). Physical activity is minimal — no outdoor play, no sports. Sleep is approximately 10 hours/night but is non-refreshing with loud snoring and daytime sleepiness. No polyuria or polydipsia. No prior treatment for weight.
Birth weight was 3.2 kg. Milestones normal. No history of steroid use, antiepileptics, or antipsychotics. No history of morning headaches, visual disturbances, or CNS insults. Family history: Father is obese; mother has type 2 diabetes. Non-consanguineous marriage. No siblings with similar complaints.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Weight | 65 kg | Significantly above 95th percentile |
| Height | 148 cm (normal for age) | Normal linear growth — favors exogenous obesity |
| BMI | 29.7 kg/m² | >95th percentile (IAP chart) — Obesity |
| Waist circumference | 94 cm | >90th percentile — Abdominal obesity / ↑cardiometabolic risk |
| BP | 128/82 mmHg | Stage 1 hypertension (for age/height) |
| HR | 88/min | Normal |
| SpO2 | 96% | Mildly reduced (OSA) |
General examination: Obese child. Normal height. No dysmorphic features. Acanthosis nigricans present at nape of neck and axillae (insulin resistance). Striae present over abdomen and thighs (thin, pale/pink — consistent with rapid weight gain; NOT violaceous striae of Cushing's). No hirsutism. No moon face or buffalo hump. No Cushingoid features.
Pubertal assessment: Tanner stage 2 (appropriate for age). Buried penis appearance due to suprapubic fat pad.
Systemic examination: Abdomen — central adiposity, no hepatomegaly. Cardiovascular — no murmurs. Respiratory — normal. No papilledema on fundoscopy.
✅ Complete Diagnosis
Exogenous (Primary) Obesity — Class 1 (BMI >95th percentile on IAP 2015 chart) with Complications: Acanthosis Nigricans (Insulin Resistance), Stage 1 Hypertension, and suspected Obstructive Sleep Apnea. No features of secondary (endogenous) obesity.
📝 History — Exam Q&A
In children under 5 years (using WHO weight-for-length/height charts):
- Overweight: ≥+2 SD to <+3 SD
- Obesity: ≥+3 SD (≥99.9th percentile)
In children 5–18 years (using IAP 2015 BMI-for-age charts):
- Overweight: BMI at or above the 85th percentile but below the 95th percentile
- Obesity (Class 1): BMI ≥95th percentile but <120% of the 95th percentile
- Obesity (Class 2): BMI ≥120% but <140% of the 95th percentile
- Obesity (Class 3): BMI ≥140% of the 95th percentile
💡 Key Point
The IAP 2015 chart uses an adult equivalent BMI of 23 kg/m² as the overweight cutoff and 27 kg/m² as the obesity cutoff at 18 years — lower than WHO cutoffs — because Asians have higher cardiometabolic risk at lower BMI values.
| Feature | Exogenous (Primary) | Endogenous (Secondary) |
|---|---|---|
| Prevalence | ~98% of cases | ~2% of cases |
| Cause | Excess calorie intake + inactivity + genetic predisposition | Hormonal, genetic syndrome, hypothalamic |
| Linear growth | Normal or tall for age | Short stature / decreased height velocity |
| Onset | Usually after infancy | May begin in infancy (syndromic/monogenic) |
| Dysmorphic features | Absent | May be present (e.g., PWS, BBS) |
| Intellectual disability | Absent | May be present |
| Family history | Often positive for obesity/T2DM | Variable |
🚨 Red Flag for Secondary Obesity
Short stature + obesity = rule out secondary cause (hypothyroidism, Cushing's, GH deficiency). In exogenous obesity, children are usually tall or of normal height.
1. Endocrine causes:
- Hypothyroidism (most common endocrine cause)
- Cushing's syndrome (exogenous steroids most common in children)
- Growth hormone deficiency
- Pseudohypoparathyroidism (Albright's hereditary osteodystrophy)
- Hyperinsulinism
2. Syndromic causes:
- Prader-Willi Syndrome (most common syndromic cause)
- Bardet-Biedl Syndrome
- Alström Syndrome
- Down Syndrome
- Turner Syndrome
3. Monogenic (rare): Leptin deficiency, leptin receptor mutation, MC4R mutation, POMC mutation
4. Hypothalamic obesity: Post-craniopharyngioma, head trauma, CNS radiation, infections
5. Drug-induced: Glucocorticoids, antipsychotics (olanzapine, risperidone), valproate, tricyclics, insulin
Dietary history:
- 24-hour diet recall or 3-day food diary
- Frequency of fast food, junk food, sugar-sweetened beverages (SSBs), fried snacks
- Portion sizes, meal patterns, skipping meals
- Night eating, emotional eating, binge eating
- Fruit and vegetable intake
Physical activity:
- Hours of outdoor play per day
- Participation in sports or structured exercise
- Mode of transport to school (walk, bus, car)
Sedentary behavior:
- Screen time (TV, mobile, computer) per day — WHO recommends <1 hr/day for 3–4 years, <2 hrs/day for older children
- Sleep duration and quality (snoring, daytime sleepiness → OSA)
- No dry skin, constipation, cold intolerance, lethargy — Rules out hypothyroidism
- No moon face, striae, muscle weakness, hypertension onset with truncal obesity — Rules out Cushing's
- No morning headaches, vomiting, visual disturbances — Rules out craniopharyngioma/hypothalamic tumor
- No CNS insult (trauma, radiation, meningitis) — Rules out hypothalamic obesity
- No steroid, valproate, antipsychotic use — Rules out drug-induced obesity
- No developmental delay, dysmorphic features — Rules out syndromic causes (PWS, BBS)
- Normal birth weight, normal early feeding — Against PWS (which has hypotonia + poor feeding in infancy)
- No polyuria/polydipsia — Rules out overt T2DM or diabetes insipidus
Genetics: Deletion of paternal 15q11-q13 (most common), maternal uniparental disomy, or imprinting defect. Incidence: 1 in 15,000–30,000.
Clinical phases:
- Infancy: Hypotonia, poor sucking, feeding difficulties, failure to thrive — often requires tube feeding
- After 18 months to 6 years: Hyperphagia develops → insatiable appetite → rapid weight gain → obesity by age 6
Key features:
- Short stature (GH deficiency)
- Hyperphagia and food-seeking behavior
- Small hands and feet, almond-shaped eyes, thin upper lip
- Hypogonadism, delayed puberty
- Intellectual disability, behavioral problems
- Elevated ghrelin levels
Diagnosis: Methylation study (DNA methylation analysis) of chromosome 15q11-13 — detects ~99% of cases.
Genetics: Autosomal recessive. Mutations in BBS genes (>20 genes identified). Rare.
Mnemonic: BROAD
- Brachyddactyly / Polydactyly (post-axial)
- Retinitis Pigmentosa (progressive visual loss — most common presenting feature)
- Obesity (central)
- Abnormal kidneys (renal anomalies)
- Developmental delay + Diabetes + Hypogonadism
Differentiating from PWS: BBS has polydactyly, retinal dystrophy, and renal anomalies; PWS has hypotonia in infancy and almond-shaped eyes.
- Parental obesity — strongest risk factor (genetic + environmental); risk is ~3× if one parent obese, ~10× if both obese
- High calorie, low-fibre diet (fast food, SSBs, processed snacks)
- Physical inactivity and high screen time
- Short sleep duration
- Formula feeding (vs breastfeeding — breastfeeding is protective)
- Maternal gestational diabetes
- High birth weight (macrosomia)
- Rapid weight gain in early infancy
- Socioeconomic and psychosocial factors (stress, food insecurity)
- Urban residence (obesogenic environment)
A simple behavioral goal-setting framework recommended by IAP for prevention of childhood obesity:
| Number | Recommendation |
|---|---|
| 5 | ≥5 servings of fruits and vegetables per day |
| 2 | ≤2 hours of recreational screen time per day |
| 1 | ≥1 hour of moderate-vigorous physical activity per day |
| 0 | 0 sugar-sweetened beverages per day |
🩺 Examination — Exam Q&A
BMI = Weight (kg) / Height (m)²
In children, BMI is interpreted using age- and sex-specific percentile charts (IAP 2015 or WHO charts) — a fixed number alone is insufficient.
Limitations of BMI:
- Cannot differentiate fat mass from lean (muscle) mass
- Does not assess fat distribution (central vs peripheral)
- May underestimate obesity in muscular children
- Ethnic differences: Asians have higher body fat % at the same BMI compared to Caucasians
Hence, waist circumference is measured in addition to BMI for cardiometabolic risk assessment.
Waist circumference (WC) is a surrogate marker of visceral (abdominal) adiposity, which is more strongly associated with cardiometabolic complications than total body fat.
- Should be measured at the midpoint between the lower rib margin and the iliac crest, after normal expiration
- Cutoff: WC ≥90th percentile on Indian-specific charts = significant abdominal obesity
- Predicts risk of hypertension, dyslipidemia, insulin resistance, and NAFLD independent of BMI
- IAP 2023 recommends routine WC measurement in all overweight/obese children
💡 Additional Measures
Waist-to-height ratio >0.5 is a simple bedside marker of cardiometabolic risk, valid across age groups and ethnicities.
Acanthosis nigricans (AN) is a velvety, hyperpigmented, hyperkeratotic skin change seen at skin folds — most commonly the nape of the neck, axillae, groin, and antecubital fossa.
Significance in obesity: AN is a clinical marker of insulin resistance. Elevated insulin levels act on insulin-like growth factor receptors in keratinocytes, stimulating their proliferation.
Key distinction: Unlike dirt/staining (which wipes off with spirit), true AN does not wipe off.
Other causes of AN in children: Type 2 diabetes, polycystic ovarian syndrome (PCOS), hypothyroidism, acromegaly, rarely malignancy (paraneoplastic).
| Feature | Exogenous Obesity | Cushing's Syndrome |
|---|---|---|
| Striae color | Pale pink, silvery white, or skin-colored | Violaceous (purple-red), wide (>1 cm) |
| Location | Abdomen, thighs, breasts | Abdomen, flanks, breasts, axillae |
| Linear growth | Normal or increased | Decreased — key differentiator |
| Moon face | Absent | Present (plethoric) |
| Buffalo hump | Absent | Present |
| Muscle wasting | Absent | Present (proximal myopathy) |
| Hypertension | Mild, secondary | Disproportionately severe |
| System | Complication | Clinical Finding |
|---|---|---|
| Metabolic | Insulin resistance | Acanthosis nigricans |
| Cardiovascular | Hypertension | Elevated BP on 3 separate occasions |
| Respiratory | Obstructive Sleep Apnea (OSA) | Tonsillar hypertrophy, reduced SpO2, snoring history |
| Orthopedic | Slipped Capital Femoral Epiphysis (SCFE) | Hip/knee pain, limited internal rotation of hip |
| Orthopedic | Blount's disease (tibia vara) | Genu varum (bowing of legs) |
| Skin | Intertrigo, acne, hirsutism (PCOS in girls) | Skin fold rashes, facial/body hair in adolescent girls |
| Neurological | Pseudotumour cerebri (IIH) | Papilledema, headache |
| Reproductive | Early puberty (girls), PCOS, buried penis (boys) | Tanner staging, external genitalia |
| Hepatic | NAFLD/MASLD | Hepatomegaly (may be present) |
In obese children, cuff size is critical. Using a small cuff gives falsely elevated readings. The bladder width should be ~40% and length ~80% of the arm circumference.
Hypertension in children: BP ≥95th percentile for age, sex, and height on three separate occasions.
- Stage 1 HTN: 95th–99th percentile + 5 mmHg
- Stage 2 HTN: >99th percentile + 5 mmHg
Obesity-related hypertension is often systolic-predominant. Always rule out secondary hypertension (renal causes, coarctation of aorta) in children.
Metabolic syndrome (MetS) is a cluster of cardiometabolic risk factors associated with insulin resistance.
IDF criteria for children ≥10 years: Central obesity (WC ≥90th percentile for age/sex) PLUS any TWO of:
- Fasting triglycerides ≥150 mg/dL
- HDL cholesterol <40 mg/dL (boys) or <50 mg/dL (girls)
- Systolic BP ≥130 mmHg or Diastolic ≥85 mmHg (or on treatment)
- Fasting glucose ≥100 mg/dL or known type 2 diabetes
Note: MetS is not diagnosed in children <10 years; weight reduction is recommended if aged 6–10 years with abdominal obesity.
🔬 Investigations — Exam Q&A
IAP 2023 recommends screening all obese children ≥10 years for comorbidities:
- Fasting blood glucose and insulin — insulin resistance, pre-diabetes, T2DM
- Fasting lipid profile — dyslipidemia (triglycerides, HDL, LDL, total cholesterol)
- Liver enzymes (ALT, AST) — NAFLD/MASLD
- Blood pressure measurement — hypertension
- Thyroid function test (TSH + Free T4) — Note: mildly elevated TSH secondary to obesity (not requiring treatment) is common
- Abdominal USG — hepatic steatosis (fatty liver)
| Suspected Cause | Investigation |
|---|---|
| Hypothyroidism | TSH + Free T4 (TSH elevated, Free T4 low = primary hypothyroidism) |
| Cushing's Syndrome | 24-hour urinary free cortisol; overnight low-dose dexamethasone suppression test (1 mg); morning serum cortisol |
| GH Deficiency | IGF-1, IGFBP-3 (low); GH stimulation test |
| Prader-Willi Syndrome | DNA methylation analysis of chromosome 15q11-q13 (detects ~99%) |
| Bardet-Biedl Syndrome | Genetic panel; ophthalmology, renal USG |
| Pseudohypoparathyroidism | Serum calcium, phosphate, PTH, X-ray (short 4th metacarpal) |
| Hypothalamic obesity | MRI brain (to detect craniopharyngioma or hypothalamic lesion) |
| Leptin deficiency | Serum leptin level (undetectable = leptin deficiency) |
💡 Important Note
Routine endocrine workup is not indicated in all obese children. IAP 2023 recommends investigating for endocrine causes only when short stature or decreased height velocity is present along with obesity, or when additional clinical clues suggest a secondary cause.
Non-alcoholic Fatty Liver Disease (NAFLD) — now renamed Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) — is the most common liver disease in obese children.
- Screening: ALT ≥2× upper limit of normal (ULN) in obese children ≥10 years — screen annually
- Ultrasound abdomen: Hyperechoic liver (fatty changes); may show hepatomegaly
- Definitive diagnosis: Liver biopsy — shows steatosis ± inflammation ± fibrosis; however, liver biopsy is rarely done in children and is reserved for severe or atypical cases
Management: Weight loss (most effective), lifestyle modification. No specific approved pharmacotherapy for pediatric NAFLD yet.
- Fasting serum insulin: Elevated (>15–20 µIU/mL suggests IR)
- HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) = [Fasting insulin (µIU/mL) × Fasting glucose (mmol/L)] / 22.5 — HOMA-IR >3.16 in adolescents suggests IR
- Fasting glucose ≥100 mg/dL = Impaired Fasting Glucose (pre-diabetes)
- OGTT (HbA1c): 2-hour glucose ≥140 mg/dL = impaired glucose tolerance; ≥200 mg/dL = diabetes
- Clinical marker: Acanthosis nigricans is the bedside indicator of insulin resistance
Bone age (X-ray left hand and wrist, compared to Greulich-Pyle atlas) helps in the differential diagnosis of obesity:
| Condition | Bone Age |
|---|---|
| Exogenous obesity | Advanced (bone age > chronological age) |
| Hypothyroidism | Delayed (significantly retarded) |
| Cushing's syndrome | Delayed |
| GH deficiency | Delayed |
Thus, a simple bone age X-ray helps quickly differentiate exogenous obesity (advanced bone age, tall) from endocrine causes (delayed bone age, short).
OSA is common in obese children due to increased pharyngeal fat deposition and adenotonsillar hypertrophy.
- Symptoms: Habitual snoring, witnessed apneas, restless sleep, night sweats, morning headaches, daytime somnolence, behavioral problems, poor school performance
- Overnight pulse oximetry: Screening tool — desaturations <90%
- Polysomnography (PSG): Gold standard — measures Apnea-Hypopnea Index (AHI); AHI >1 event/hr is abnormal in children
Management: Adenotonsillectomy (if tonsillar hypertrophy), weight loss, CPAP for moderate-severe OSA without surgical indication.
💊 Management — Exam Q&A
Management is stepwise and multidisciplinary (pediatrician, dietitian, psychologist, physiotherapist):
- Step 1 (All obese children): Lifestyle modification — dietary changes + physical activity + behavioral therapy (family-based)
- Step 2 (If lifestyle fails after 6 months): Intensive health behavior and lifestyle treatment (IHBLT) — structured, supervised program with ≥26 contact hours over 3–12 months
- Step 3 (Class 3, or Class 2 with life-threatening comorbidities): Pharmacotherapy as adjunct to lifestyle
- Step 4 (Class 2 + comorbidities, Class 3, age >12 years, after failure of all above): Bariatric surgery
Key principle: The entire family must be involved. Stigma-free, compassionate approach. Treat co-morbidities concurrently.
- Calorie deficit: 500–600 kcal/day deficit leads to ~0.5–1 kg/week weight loss
- Balanced diet with adequate protein; high fibre, low glycaemic index foods
- Eliminate SSBs (soft drinks, packaged juices, energy drinks) — 0 per day
- Eliminate fast food, ultra-processed snacks, fried food
- Encourage 5 servings of fruits and vegetables per day
- Structured meal timings; avoid eating while watching screens
- Family eating together — same healthy food for all household members
- Goal: Not rapid weight loss but slowing the rate of weight gain, then maintenance, in growing children
- Minimum: 60 minutes of moderate-to-vigorous physical activity (MVPA) per day — for all children 5–17 years (WHO)
- Aim for vigorous activity (running, swimming, cycling) at least 3 days/week
- Include muscle-strengthening and bone-strengthening activities 3 days/week
- Reduce sedentary time: Screen time ≤2 hours/day (AAP recommendation for school-age children)
- For very obese or OSA children, begin with low-impact activities (walking, swimming)
- Activity should be enjoyable, age-appropriate, and family-based to ensure adherence
IAP 2023: Pharmacotherapy may be offered only as an adjunct to lifestyle modification — never as monotherapy.
Indications:
- Class 3 obesity (BMI ≥140% of 95th percentile)
- Class 2 obesity with life-threatening comorbidities
- Age ≥12 years
- After failure of at least 6 months of lifestyle modification
| Drug | Mechanism | Approved Age | Notes |
|---|---|---|---|
| Orlistat | Pancreatic lipase inhibitor → reduces fat absorption by ~30% | ≥12 years | 120 mg TID with meals; SE: steatorrhoea, flatulence, fat-soluble vitamin deficiency |
| Metformin | Reduces hepatic glucose output, improves insulin sensitivity | ≥10 years (for T2DM); off-label for obesity | Particularly useful in obesity with insulin resistance or pre-diabetes |
| Liraglutide (GLP-1 RA) | Increases satiety, slows gastric emptying, reduces appetite | ≥12 years (FDA approved 2020) | SC injection once daily; significant BMI reduction; SE: nausea, vomiting |
| Semaglutide (GLP-1 RA) | Same as liraglutide, longer-acting weekly formulation | ≥12 years (FDA approved 2022) | SC injection once weekly; greatest efficacy; SE: GI symptoms |
| Phentermine + Topiramate | CNS appetite suppression + satiety promotion | ≥12 years (off-label in some countries) | Not approved in India; teratogenic |
Efficacy criterion (IAP): Drug is deemed ineffective if it fails to safely reduce BMI by ≥5% over 12 weeks of consistent use.
Indications (IAP 2023):
- Age >12 years
- Class 2 obesity (BMI ≥120% of 95th percentile) with significant comorbidities (T2DM, OSA, hypertension, NAFLD) OR
- Class 3 obesity (BMI ≥140% of 95th percentile) — with or without comorbidities
- After failure of ≥6 months of intensive lifestyle modifications + pharmacotherapy
Types of procedures:
- Sleeve Gastrectomy: Most common in adolescents — ~80% of stomach removed; restrictive; irreversible
- Roux-en-Y Gastric Bypass: Combined restrictive + malabsorptive; more effective for T2DM; higher complication rate
- Adjustable Gastric Banding: Largely abandoned in adolescents due to high revision rates
🚨 Prerequisites for Surgery
Attainment of Tanner stage 4–5 puberty, skeletal maturity near adult height, psychological evaluation, commitment to lifelong follow-up, and nutritional supplementation post-surgery (vitamins B12, D, calcium, iron).
- First-line: Lifestyle modification — weight loss (even 5–10% weight loss can significantly reduce BP), low-sodium diet, physical activity
- Pharmacotherapy: If BP remains elevated or Stage 2 HTN at diagnosis
- Drug of choice: ACE inhibitor (e.g., Enalapril) or ARB (e.g., Losartan) — particularly preferred if insulin resistance/T2DM coexists (renoprotective)
- Calcium channel blockers (Amlodipine) are an alternative
- Avoid β-blockers as first-line in obese children (worsen insulin resistance and dyslipidemia)
- Lifestyle modification is the cornerstone in mild cases
- Metformin — first-line drug; approved ≥10 years; dose: 500 mg OD, increase to 1000 mg BD. Benefits: weight loss, improves insulin sensitivity
- Insulin: If HbA1c >9% or symptomatic hyperglycemia at diagnosis
- GLP-1 receptor agonists (Liraglutide, Semaglutide): Approved for T2DM in adolescents ≥10 years; promote both glycemic control and weight loss
- Bariatric surgery can induce remission of T2DM in severely obese adolescents
- Growth hormone therapy: Improves linear growth, body composition (reduces fat, increases lean mass), and cognitive function — started early in life, even in infancy
- Dietary restriction: Strict calorie control; food must be secured (locked fridges) due to food-seeking behavior
- Behavioral management: Routine structure, behavior modification
- Hormone replacement: Sex hormones for hypogonadism at appropriate age
- Physiotherapy and speech therapy for hypotonia and developmental issues
- Emerging: Intranasal oxytocin (trials ongoing); anti-ghrelin therapies
- Bariatric surgery is controversial in PWS — high risk of perioperative complications due to behavioral issues and respiratory problems
🔭 Recent Advances — Exam Q&A
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the most significant pharmacological advance in obesity management.
Mechanism: Mimic GLP-1 (an incretin) → increase insulin secretion (glucose-dependent), slow gastric emptying, reduce appetite via hypothalamic pathways → weight loss.
- Liraglutide (Saxenda): FDA approved 2020 for adolescents ≥12 years with obesity; SC injection daily; achieves ~5% BMI reduction
- Semaglutide (Wegovy): FDA approved December 2022 for adolescents ≥12 years; once-weekly SC injection; achieves ~14–17% body weight reduction — most efficacious AOM to date in adolescents
Side effects: Nausea, vomiting, diarrhea (usually transient). Rare: Pancreatitis. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2.
Limitation: Weight regain upon discontinuation — need for long-term/chronic use; expensive; not yet widely available/approved in India for pediatric use.
Tirzepatide is a dual GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonist — currently the most potent anti-obesity medication available.
- Approved by FDA for adults (2023, Zepbound brand for obesity)
- Achieves ~20–22% weight loss in adults — superior to any single incretin-based therapy
- Pediatric trials are ongoing — not yet approved for children/adolescents
- Mechanism: Synergistic effect of GLP-1 (satiety, insulin, gastric emptying) + GIP (enhanced insulin secretion, adipogenesis reduction)
Represents the frontier of obesity pharmacotherapy; expected to be approved for adolescents in coming years.
The leptin-melanocortin pathway is a key energy-regulating axis in the hypothalamus:
Adipose tissue → Leptin → Hypothalamus → POMC neurons → MC4R → satiety signals.
- Leptin deficiency: Rare monogenic cause; treated with recombinant human leptin (metreleptin) — dramatically reduces hyperphagia and normalizes weight
- MC4R mutations: Most common monogenic cause of severe early-onset obesity (~2–5% of severely obese children); treated with Setmelanotide (MC4R agonist) — FDA approved 2020 for POMC deficiency, PCSK1 deficiency, and leptin receptor deficiency
- POMC mutation: Treated with setmelanotide; also causes hypocortisolism (requires hydrocortisone replacement)
Genetic testing for these rare monogenic forms is now recommended in children with severe obesity onset before age 5 years, especially with extreme hyperphagia.
In 2025, a global commission on obesity proposed a paradigm shift in defining obesity — moving beyond BMI alone:
- BMI + at least one additional anthropometric measure (waist circumference, waist-to-hip ratio, or waist-to-height ratio) PLUS
- Evidence of organ dysfunction or functional limitations in activities of daily living
Children with excess adiposity but no organ dysfunction or functional impairment are classified as having "preclinical obesity" — requiring prevention and monitoring, but not necessarily aggressive treatment.
This approach reduces stigma, recognizes obesity as a chronic disease with measurable impact, and guides targeted management.
The American Academy of Pediatrics (AAP) published its first comprehensive clinical practice guideline for pediatric obesity in January 2023. Key changes:
- Avoid delayed approach: No "watchful waiting" — early, active treatment from the point of diagnosis
- Intensive health behavior and lifestyle treatment (IHBLT) with ≥26 contact hours is the foundation
- Pharmacotherapy offered earlier: For children ≥12 years with BMI ≥95th percentile — no longer a last resort after prolonged lifestyle failure
- Bariatric surgery for adolescents ≥13 years with BMI ≥120% of the 95th percentile — should be offered referral to qualified centers
- Explicitly discourages weight stigma and bias in clinical settings
- Calls for systemic and policy-level interventions
In 2023, international hepatology societies adopted new nomenclature:
- NAFLD (Non-Alcoholic Fatty Liver Disease) → renamed MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease)
- NASH (Non-Alcoholic Steatohepatitis) → renamed MASH (Metabolic dysfunction-Associated Steatohepatitis)
This change reflects the understanding that the condition is driven by metabolic dysfunction (obesity, insulin resistance, diabetes, hypertension, dyslipidemia) rather than simply the absence of alcohol. The term is also less stigmatizing.
Pediatric MASLD prevalence: ~5–10% of children; up to 40–70% in obese children. The disease can progress to fibrosis and cirrhosis in childhood.
⚡ Key Points — Quick Revision
🧮 Quick BMI Calculator
One-Liners for Exam
- BMI formula: Weight (kg) / Height (m)²
- Obesity in 5–18 years: BMI ≥95th percentile on IAP 2015 chart
- IAP obesity cutoff at 18 years: Adult equivalent BMI of 27 kg/m²
- Exogenous obesity = TALL; Endogenous obesity = SHORT
- Most common secondary cause: Hypothyroidism (endocrine); Prader-Willi (syndromic)
- Most common monogenic cause: MC4R (melanocortin-4 receptor) mutation
- Acanthosis nigricans: Marker of insulin resistance
- Violaceous striae: Think Cushing's (not exogenous obesity)
- Bone age: Advanced in exogenous obesity; Delayed in hypothyroidism/Cushing's
- Waist circumference ≥90th percentile: Abdominal obesity — screen for metabolic syndrome
- HOMA-IR >3.16: Insulin resistance in adolescents
- 5-2-1-0 rule: 5 fruits/vegetables, ≤2 hrs screen time, 1 hr MVPA, 0 SSBs
- Pharmacotherapy: Adjunct only; age ≥12 years; after ≥6 months lifestyle failure
- Most efficacious AOM: Semaglutide (GLP-1 RA) — ~14–17% weight loss
- Orlistat: FDA approved ≥12 years; inhibits pancreatic lipase; SE: steatorrhoea
- Bariatric surgery: Age >12 years; Class 2 + comorbidities OR Class 3; after failure of lifestyle + pharmacotherapy
- PWS treatment: Growth hormone therapy + strict dietary restriction + food security
- Leptin deficiency: Treated with recombinant leptin (metreleptin)
- MC4R/POMC deficiency: Treated with Setmelanotide
- NAFLD now called: MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease)
- OSA gold standard: Polysomnography (AHI >1/hr abnormal in children)
- HTN in obesity: ACE inhibitor/ARB preferred; avoid β-blockers as first-line
- AAP 2023: No watchful waiting — early active treatment from diagnosis
Complications of Childhood Obesity — System-wise
| System | Complication |
|---|---|
| Metabolic | Insulin resistance, Pre-diabetes, Type 2 DM, Dyslipidemia, Metabolic syndrome |
| Cardiovascular | Hypertension, Left ventricular hypertrophy, Atherosclerosis (early) |
| Hepatic | MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) / MASH |
| Respiratory | Obstructive Sleep Apnea (OSA), Obesity Hypoventilation Syndrome, Asthma |
| Endocrine | Early puberty (girls), PCOS, Hypogonadism (boys) |
| Orthopedic | Slipped Capital Femoral Epiphysis (SCFE), Blount's Disease (tibia vara), Flat feet, Knee pain |
| Neurological | Pseudotumour cerebri / Idiopathic Intracranial Hypertension (IIH) |
| Psychological | Depression, Low self-esteem, Bullying, Eating disorders |
| Renal | Glomerulopathy (focal segmental glomerulosclerosis), Proteinuria |
| GI | GERD, Gallstones (cholelithiasis) |
| Long-term | Tracking into adult obesity, cardiovascular disease, early mortality |